BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+30.37%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$12B
AUM Growth
+$12B
(+23%)
Cap. Flow
-$219M
Cap. Flow
% of AUM
-1.82%
Top 10 Holdings %
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10
Top Buys
| 1 |
NVTA
Invitae Corporation
NVTA
|
$110M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$103M |
| 3 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
$97.5M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$60.6M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$35.9M |
Top Sells
| 1 |
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
|
$653M |
| 2 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
$73M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
$25.3M |
| 4 |
PCYC
PHARMACYCLICS INC
PCYC
|
$22.9M |
| 5 |
Xoma
XOMA
|
$8.06M |
Sector Composition
| 1 | Healthcare | 40.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DSCI
26
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $29.3M | 0.24% |
3,457,841
-79,296
| -2% | -$672K |
|
|
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $26M | 0.22% |
4,350,808
-98,989
| -2% | -$592K |
|
|
ACGN
28
DELISTED
Aceragen, Inc. Common Stock
ACGN
| $25.8M | 0.21% |
6,965,432
+5,337,260
| +328% | +$19.8M |
|
|
ALDR
29
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $25.4M | 0.21% |
879,581
+726,231
| +474% | +$21M |
|
|
ACOR
30
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $24.6M | 0.2% |
738,916
-16,618
| -2% | -$553K |
|
31
Gilead Sciences
GILD
$140B
| $24.5M | 0.2% |
249,995
-6,113
| -2% | -$600K |
|
32
Sangamo Therapeutics
SGMO
$165M
| $22M | 0.18% |
1,404,544
+449,212
| +47% | +$7.04M |
|
33
Neurocrine Biosciences
NBIX
$13.9B
| $21.5M | 0.18% |
542,236
-12,354
| -2% | -$491K |
|
|
KYTH
34
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $17.8M | 0.15% |
354,265
+68,010
| +24% | +$3.41M |
|
|
BLUE
35
DELISTED
bluebird bio
BLUE
| $17.7M | 0.15% |
146,581
-3,419
| -2% | -$413K |
|
|
RPRX
36
DELISTED
Repros Therapeutics Inc.
RPRX
| $17.2M | 0.14% |
2,000,000
| – | – |
|
|
FOMX
37
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $16.9M | 0.14% |
1,821,967
+800,367
| +78% | +$7.4M |
|
|
38
Vanda Pharmaceuticals
VNDA
$281M
| $16.3M | 0.14% |
1,750,230
-2,721,923
| -61% | -$25.3M |
|
39
Novavax
NVAX
$1.24B
| $16.1M | 0.13% |
1,945,687
+722,325
| +59% | +$5.97M |
|
40
Iovance Biotherapeutics
IOVA
$800M
| $16M | 0.13% |
+1,325,000
| New | +$16M |
|
|
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
| $15M | 0.13% |
202,630
| – | – |
|
42
Agios Pharmaceuticals
AGIO
$2.36B
| $14.1M | 0.12% |
149,954
-13,439
| -8% | -$1.27M |
|
43
Omeros
OMER
$283M
| $14M | 0.12% |
637,446
-10,655
| -2% | -$235K |
|
44
Xencor
XNCR
$586M
| $13.4M | 0.11% |
872,072
+280,701
| +47% | +$4.3M |
|
|
MTEM
45
DELISTED
Molecular Templates, Inc.
MTEM
| $11.9M | 0.1% |
2,925,519
+770,003
| +36% | +$3.13M |
|
46
Arcturus Therapeutics
ARCT
$476M
| $10.1M | 0.08% |
1,789,871
+1,500,000
| +517% | +$8.45M |
|
47
Neurogene
NGNE
$278M
| $9.76M | 0.08% |
1,187,666
-22,684
| -2% | -$186K |
|
48
MacroGenics
MGNX
$121M
| $9.57M | 0.08% |
305,043
-6,848
| -2% | -$215K |
|
|
AERI
49
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $9.38M | 0.08% |
299,356
| – | – |
|
50
Ultragenyx Pharmaceutical
RARE
$3.08B
| $9.25M | 0.08% |
148,894
-1,106
| -0.7% | -$68.7K |
|